Suppr超能文献

急性次大面积肺栓塞溶栓治疗的疗效与安全性:随访研究

Efficacy and Safety of Thrombolytic Therapy in Acute Submassive Pulmonary Embolism: Follow-Up Study.

作者信息

Sinha Santosh Kumar, Sachan Mohit, Goel Amit, Singh Karandeep, Mishra Vikas, Jha Mukesh Jitendra, Kumar Ashutosh, Abdali Nasar, Asif Mohammad, Razi Mahamdula, Pandey Umeshwar, Thakur Ramesh, Varma Chandra Mohan, Krishna Vinay

机构信息

Department of Cardiology, LPS Institute of Cardiology, G.S.V.M. Medical College, Kanpur, Uttar Pradesh 208002, India.

出版信息

J Clin Med Res. 2017 Feb;9(2):163-169. doi: 10.14740/jocmr2829w. Epub 2016 Dec 31.

Abstract

BACKGROUND

Thrombolysis in acute submassive pulmonary embolism (PE) remains controversial. So we studied impact of thrombolytic therapy in acute submassive PE in terms of mortality, hemodynamic status, improvement in right ventricular function, and safety in terms of major and minor bleeding.

METHOD

A single-center, prospective, randomized study of 86 patients was conducted at LPS Institute of Cardiology, G.S.V.M. Medical College, Kanpur, India. Patients received thrombolysis (single bolus of tenecteplase) with unfractionated heparin (UFH, group I) or placebo with UFH (group II).

RESULT

Mean age of patients was 54.35 ± 12.8 years with male dominance (M:F = 70%:30%). Smoking was the most common risk factor seen in 29% of all patients, followed by recent history of immobilization (25%), history of surgery or major trauma within past 1 month (15%), dyslipidemia (10%) and diabetes mellitus (10%). Dyspnea was the most common symptom in 80% of all patients, followed by chest pain in 55% and syncope in 6%. Primary efficacy outcome occurred significantly better in group I vs. group II (4.5% vs. 20%; P = 0.04), and significant difference was also found in hemodynamic decompensation (4.5% vs. 20%; P = 0.04), the fall in mean pulmonary artery systolic pressure (PASP) (28.8% vs. 22.5%; P = 0.03), improvement in right ventricular (RV) function (70% vs. 40%; P = 0.001) and mean hospital stay (8.1 ± 2.5 vs. 11.1 ± 2.14 days; P = 0.001). There was no difference in mortality and major bleeding as safety outcome but increased minor bleeding occurred in group I patients (16% vs. 12%; P = 0.04).

CONCLUSION

Patients with acute submassive PE do not derive overall mortality benefit, recurrent PE and rehospitalization with thrombolytic therapy but had improved clinical outcome in form of decrease in hemodynamic decompensation, mean hospital stay, PASP and improvement of RV function with similar risk of major bleed but at cost of increased minor bleeding.

摘要

背景

急性次大面积肺栓塞(PE)的溶栓治疗仍存在争议。因此,我们从死亡率、血流动力学状态、右心室功能改善情况以及严重和轻微出血的安全性方面研究了溶栓治疗对急性次大面积肺栓塞的影响。

方法

在印度坎普尔市G.S.V.M.医学院LPS心脏病学研究所对86例患者进行了一项单中心、前瞻性、随机研究。患者接受替奈普酶单次推注溶栓治疗并联合普通肝素(UFH,I组)或接受安慰剂联合UFH治疗(II组)。

结果

患者的平均年龄为54.35±12.8岁,男性居多(男:女 = 70%:30%)。吸烟是最常见的危险因素,在所有患者中占29%,其次是近期制动史(25%)、过去1个月内的手术或重大创伤史(15%)、血脂异常(10%)和糖尿病(10%)。呼吸困难是所有患者中最常见的症状,占80%,其次是胸痛,占55%,晕厥占6%。I组的主要疗效指标显著优于II组(4.5%对20%;P = 0.04),在血流动力学失代偿方面也存在显著差异(4.5%对20%;P = 0.04),平均肺动脉收缩压(PASP)下降(28.8%对22.5%;P = 0.03),右心室(RV)功能改善(70%对40%;P = 0.001)以及平均住院时间(8.1±2.5天对11.1±2.14天;P = 0.001)。作为安全性指标的死亡率和严重出血无差异,但I组患者的轻微出血增加(16%对12%;P = 0.04)。

结论

急性次大面积肺栓塞患者接受溶栓治疗并不能在总体死亡率、复发性肺栓塞和再次住院方面获益,但在血流动力学失代偿、平均住院时间、PASP降低以及右心室功能改善等方面的临床结局有所改善,严重出血风险相似,但代价是轻微出血增加。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/067b/5215020/513c1088f185/jocmr-09-163-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验